Abstract
Despite potent statin therapy, residual risk of CVD events remains unacceptably high. Atherogenic lipoprotein particles and subclass distribution on statin therapy may identify markers of residual risk. Among 11,984 participants in JUPITER ([NCT00239681][1]; AstraZeneca) with lipoproteins measured
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
